Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi's rare disease drug Enjaymo finds yet another home, with Italian drugmaker Recordati paying $825 million upfront plus up to $250 million in milestones…
Recordati SpA is buying the rare disease drug Enjaymo (sutimlimab) from Sanofi SA for $825 million up front and up to $250 million in commercial milestones,…
Enjaymo contributed EUR 146.3 million in FY2025, +26.7% vs full year 2024 proforma, within the Hema-Oncology franchise.
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Recordati announced agreement to acquire global rights to Enjaymo (sutimlimab) from Sanofi (top-25 pharma seller) for $825M upfront plus up to $250M in commercial milestones. Enjaymo is the only FDA-approved treatment for cold agglutinin disease (CAD), generating ~€100M TTM revenue with peak sales potential of €250-300M. Strengthens Recordati rare disease franchise.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Recordati S.p.A. / Sanofi SA (this deal) | 2024 | $1.1B | — |
| Recordati S.p.A. / EUSA Pharma (UK) Ltd. | 2022 | $845M | — |
| Recordati S.p.A. / Ionis Pharmaceuticals, Inc. | 2026 | — | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
← Browse all deals · How we score deals
More: 2024 deals · Recordati S.p.A. deals · Hematology deals